Research programme: Canavan disease therapeutics - Turing PharmaceuticalsAlternative Names: TUR-007
Latest Information Update: 21 Nov 2015
At a glance
- Originator Turing Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Canavan disease